4.5 Article

Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016

期刊

BMC INFECTIOUS DISEASES
卷 20, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12879-020-05261-7

关键词

HIV; AIDS; Late presentation; Avoidable events; Eastern Europe; HIV testing

资金

  1. ViiV Healthcare LLC
  2. Janssen Scientific Affairs
  3. Janssen RD
  4. Bristol-Myers Squibb Company
  5. Merck Sharp Dohme Corp
  6. Gilead Sciences
  7. European Union [260694]
  8. Swiss National Science Foundation [148522]
  9. Danish National Research Foundation [DNRF126]
  10. International Cohort Consortium of Infectious Disease (RESPOND)
  11. Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS), France
  12. HIV Monitoring Foundation, The Netherlands
  13. Augustinus Foundation, Denmark
  14. European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant [260694]

向作者/读者索取更多资源

BackgroundLate presentation (LP), defined as a CD4 count <350/mm(3) or an AIDS-event at HIV-diagnosis, remains a significant problem across Europe. Linking cohort and surveillance data, we assessed the country-specific burden of LP during 2010-2016 and the occurrence of new AIDS events or deaths within 12months of HIV-diagnosis believed to be attributable to LP.MethodsCountry-specific percentages of LP and AIDS-events/death rates (assessed with Poisson regression) observed in The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and EuroSIDA cohorts, were applied to new HIV-diagnoses reported to the European Centre for Disease Prevention and Control. The estimated number of LP in the whole population was then calculated, as was the number of excess AIDS-events/deaths in the first 12months following HIV-diagnosis assumed to be attributable to LP (difference in estimated events between LP and non-LP).ResultsThirty-nine thousand two hundred four persons were included from the COHERE and EuroSIDA cohorts, of whom 18,967 (48.4%; 95% Confidence Interval [CI] 47.9-48.9) were classified as LP, ranging from 36.9% in Estonia (95%CI 25.2-48.7) and Ukraine (95%CI 30.0-43.8) to 64.2% in Poland (95%CI 57.2-71.3). We estimated a total of >320,000 LP and 12,050 new AIDS-events/deaths attributable to LP during 2010-2016, with the highest estimated numbers of LP and excess AIDS-events/deaths in Eastern Europe. Country-level estimates of excess events ranged from 17 AIDS-events/deaths (95%CI 0-533) in Denmark to 10,357 (95%CI 7768-147,448) in Russia.ConclusionsAcross countries in Europe, the burden of LP was high, with the highest estimated number of LP and excess AIDS-events/deaths being in Eastern Europe. Effective strategies are needed to reduce LP and the attributable morbidity and mortality that could be potentially avoided.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据